Advances in acute myeloid leukemia
- PMID: 34615640
- DOI: 10.1136/bmj.n2026
Advances in acute myeloid leukemia
Abstract
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis and disease progression have led to novel therapies for AML. Ongoing research and clinical trials are actively seeking to personalize therapy by identifying molecular targets, discovering patient specific and disease specific risk factors, and identifying effective combinations of modalities and drugs. This review focuses on important updates in diagnostic and disease classifications that reflect new understanding of the biology of AML, its mutational heterogeneity, some important genetic and environmental risk factors, and new treatment options including cytotoxic chemotherapy, novel targeted agents, and cellular therapies.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.
Similar articles
-
Precision therapy for acute myeloid leukemia.J Hematol Oncol. 2018 Jan 5;11(1):3. doi: 10.1186/s13045-017-0543-7. J Hematol Oncol. 2018. PMID: 29301553 Free PMC article. Review.
-
Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.Curr Hematol Malig Rep. 2019 Oct;14(5):386-394. doi: 10.1007/s11899-019-00535-7. Curr Hematol Malig Rep. 2019. PMID: 31350639 Review.
-
Acute Myeloid Leukemia: A Review.R I Med J (2013). 2020 Apr 1;103(3):38-40. R I Med J (2013). 2020. PMID: 32236160 Review.
-
Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia.Bosn J Basic Med Sci. 2021 Aug 1;21(4):409-421. doi: 10.17305/bjbms.2020.5485. Bosn J Basic Med Sci. 2021. PMID: 33577442 Free PMC article. Review.
-
Novel Therapies in Acute Myeloid Leukemia.Semin Oncol Nurs. 2019 Dec;35(6):150955. doi: 10.1016/j.soncn.2019.150955. Epub 2019 Nov 20. Semin Oncol Nurs. 2019. PMID: 31759818 Review.
Cited by
-
RNA modification in normal hematopoiesis and hematologic malignancies.MedComm (2020). 2024 Oct 23;5(11):e787. doi: 10.1002/mco2.787. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39445003 Free PMC article. Review.
-
Identification of the immunosuppressive effect of γδ T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia.Front Immunol. 2022 Oct 17;13:1009709. doi: 10.3389/fimmu.2022.1009709. eCollection 2022. Front Immunol. 2022. PMID: 36325350 Free PMC article.
-
MICAL1 promotes the proliferation in acute myeloid leukemia and is associated with clinical prognosis and immune infiltration.Discov Oncol. 2024 Jul 12;15(1):279. doi: 10.1007/s12672-024-01150-6. Discov Oncol. 2024. PMID: 38995414 Free PMC article.
-
Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.Blood Adv. 2024 Apr 9;8(7):1747-1759. doi: 10.1182/bloodadvances.2023012529. Blood Adv. 2024. PMID: 38324726 Free PMC article.
-
Immunogenic cell death (ICD) genes predict immunotherapy response and therapeutic targets in acute myeloid leukemia (AML).Front Genet. 2024 Aug 14;15:1419819. doi: 10.3389/fgene.2024.1419819. eCollection 2024. Front Genet. 2024. PMID: 39205940 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
